Meropenem Pontus Pharma D.O.O. (Meropenem Trihydrate)

Meropenem works by binding to penicillin‑binding proteins on bacterial cell walls, inhibiting the final step of peptidoglycan cross‑linking. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its structure provides stability against most β‑lactamases, giving it activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms.

The specific dose of Meropenem Pontus Pharma D.O.O. is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and local susceptibility patterns. Dosing regimens are individualized and should follow institutional guidelines or the product’s prescribing information.

Safety data for Meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Meropenem and imipenem belong to the same carbapenem class but differ in stability and spectrum. Meropenem is more stable against renal dehydropeptidase‑I, allowing use without a renal protective agent, and has a slightly broader activity against Pseudomonas aeruginosa. Both require dose adjustment in renal impairment and share similar safety profiles.

Meropenem Pontus Pharma D.O.O. should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking. If the product reaches room temperature for a short period during administration, it may be used promptly but should be returned to refrigeration if not used.

Meropenem is administered intravenously, typically as a bolus or short infusion over 15‑30 minutes. The infusion rate and dosing interval are selected by the prescriber based on infection severity, renal function and pharmacokinetic targets. Administration should follow aseptic technique and institutional infusion protocols.

Serious risks include hypersensitivity reactions such as anaphylaxis, seizure activity especially in patients with renal dysfunction or pre‑existing CNS disorders, and Clostridioides difficile‑associated colitis. Monitoring for neurological signs, allergic symptoms and gastrointestinal disturbances is essential during treatment.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment without dose adjustment, or those receiving drugs that significantly lower the seizure threshold.